How has the product line changed from "Health Materials Factory" to "Stone Pharmaceutical Group"?

Themost of the large pharmaceutical companies in China, often have experienced decades of development, the process is almost witnessed the changes in China's pharmaceutical market demand, a sense of historyFrom the 1938 Yanzhong Military District Health Materials Factory, to the establishment of the Group in 1997, "Stone Pharmaceutical Group" has now developed into one of china's few large pharmaceutical companiesAnd whether it is the domestic tradition of much-needed imitation varieties, or so far a few of the small number of new drugs listed, stone pharmaceutical groups are appearing more and more frequently, its development has touched the domestic and even foreign pharmaceutical industry sensitive nerves01,Stone Pharmaceutical Group Development Memorabilia
1938, Yanzhong Military District Health Materials Factory for the predecessor of stone pharmaceutical group, mainly producing medical materials for war; Production; in 2003, Stone Pharmaceutical Group was listed in Hong Kong; in 2004, Enbip (butyl benzene) was listed; in 2008, Wenchuan earthquake, Shipharma Group donated 12 million yuan in medicine and cash for the first time, and employees donated 1.07 million yuan spontaneously; and in 2018, Stone Pharmaceutical Group became the first pharmaceutical stock in the nearly 50 years since the establishment of the Hang Seng Index02,Stone Pharmaceutical Group in recent yearsAccording to the company's official website: the Group's total existing assets of 41 billion yuan, 25,000 employees; SZ) successfully listed on the GEM, Stone Pharmaceutical Group has achieved a "red-chip plus A" financing pattern of the new eraAccording to the 2019 Interim Report, group revenue for the six months ended June 30, 2019 was RMB11.178 billion, up 27.6% YoY; RMB, up 36.8% YoY, and Innovative Pharmaceutical products achieved sales of RMB 6.149 billion in the first half of 2019, up 55.4% YoY, with Embip up 35.9% and Anti-Tumor Drug Portfolio up 194.2%, the two pillars of the Group's growth03,Stone Pharmaceutical Group Research and Development SystemStone Pharmaceutical Group has its own high-tech drug incubation base - Stone Pharmaceutical Group Central Pharmaceutical Research Institute, in the United States, California, Preston, Texas, New Jersey has a research and development center and clinical center; Has established a research and development team of 1,700 people, including thousands of master's, doctoral and other highly educated personnel, and in innovative drugs, generic drugs, biological drugs, antibody drugs, etc, set up a complete research and development systemAccording to the interim report, the investment in research and development in the first half of 2019 was RMB942 million, an increase of 68.5% YoY, accounting for about 10.7% of the revenue of the pharmaceutical businessAt present, there are more than 300 research projects, including 40 new small moleculedrugs, 30 new target macromolecule biologicdrugs, mainly concentrated in cardiovascular diseases, anti-tumor, diabetes, psychoneuropathy and anti-infection fields 04, 2000 - so far / Drug Registration Statistics Since 2000 to date, the number of registered declarations of stone pharmaceutical group varieties is nearly a thousand, by the 10 subsidiaries to declare; 05, the key products in the pharmaceutical business
Enbip (butyl benzene softgels and injections) Enbig is China's 3rd country with independent intellectual property rights of 1 new drug, for acute ischemic stroke treatment, into China's multiple stroke-related treatment guidelines, both dosage forms have been included in the national health insurance catalog; Xuanning (Malay acid l-aminochloride and dispersal tablets) Xuanning is mainly used to treat hypertension, chronic stability angina and mutant angina, Xuanning has successfully submitted a new drug listing application to the U.S FDA, for The First time for Chinese pharmaceutical companies to the U.S FDA to submit a new drug listing application The Group is transforming Xuanning's sales model to self-employed model and strengthening the development of the grass-roots and pharmacy markets below the county level in order to gain greater market share and increase sales growth Zinyuli (polyglycol recombinant human granulocyte stimulation factor injection) Jin Yuli is the first long-term blood-raising drug developed independently in China, which can reduce the chance of infection due to low number of white blood cells in patients undergoing chemotherapy, and ensure that the standard chemotherapy dose is implemented, the species has been awarded the Chinese patent gold medal, is seeking immunotherapy and targeted treatment of the combined drug use opportunities ke Aili (injection with yew alcohol) the first model of the domestic market of a new generation of yew alcohol chemotherapy drugs, after the listing successfully passed the consistency evaluation, won the 2018 "China's most innovative formulation varieties"; At present, the species is used in the treatment of breast cancer, is expanding in lung cancer, pancreatic cancer, stomach cancer, melanoma, urinary tract cancer, head and neck nasopharyngeal cancer, esophageal cancer and other applications Nolinin (imatininin tablets) nolinin is mainly used to treat non-genuine chromosome-positive chronic myeloid leukemia and Philadelphia chromosomal-positive acute lymphoblastic leukemia, as well as for the treatment of gastrointestinal mesoplasmic tumors; in addition to the above varieties, the company sales growth of higher varieties are aspirin intestinal tablets, methylcobalamin tablets, metformin hydrochloride and so on; 06, in the research of innovative drug pipeline introduction through data query, Stone Pharmaceutical Group's current innovative drug pipeline has been layered, in addition to the listed class of 1 new drugs, all clinical stages have varieties in the research; FR, VEGFR, RANKL, HER2, IFNAR, etc., are popular targets, but have not yet been involved in the current extremely hot PD-1/PD-L1, etc ; reference: 1 Stone Pharmaceutical Group Co., Ltd .2019 Interim Report 2 Stone Pharmaceutical Group Co., Ltd.
Cortellis Data